الفهرس Only 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
As about 90% of colorectal cancers and 50% of hepatocellular carcinoma have activated Wnt/Ý-catenin signaling, the current study aim to examine the effect of knocking down Ý-catenin on the expression of VEGF-A and Slug as well as the apoptosis related genes; NF-mB, FasR and c-Flip in HepG2 cells and the possible alteration of their expression when combined with Bevacizumab. Expression of VEGF-A and Slug was also studied in Caco-2 cells. It is reported in this study that VEGF-A increases significantly in response to Bevacizumab alone in HepG2, while VEGF-A and Slug decreased significantly when Bevacizumab was combined with knocked down Ý-catenin in HepG2. However, Bevacizumab alone is more effective in reducing the expression of those genes in Caco-2. On the other hand, Bevacizumab combined with knocked down Ý-catenin remarkably reduced the level of NF-mB, FasR and c-Flip compared to Bevacizumab only treated HepG2 cells although the difference was not statistically significant